[What do we know today about neuroleptic malignant syndrome?]

Area of Science:

• Neuroscience
• Pharmacology
• Internal Medicine

Background:

• Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of neuroleptic medication.
• It can also occur after abrupt withdrawal of dopaminergic agonists.
• Untreated NMS carries a high mortality rate of approximately 20%.

Observation:

• NMS symptoms can manifest within 24 hours of initiating neuroleptic treatment.
• The syndrome presents as a tetralogy: extrapyramidal symptoms, altered consciousness, hyperthermia, and autonomic instability.
• Secondary laboratory findings include elevated creatine kinase and leukocyte count.

Findings:

• Treatment involves immediate cessation of neuroleptic drugs.
• Therapeutic interventions include dopaminagonists, benzodiazepines, and fluid replacement.
• Neuroleptic readministration may be considered after a 1-4 week break if psychotic relapse occurs.

Implications:

• Prompt diagnosis and management of NMS are critical to reduce mortality.
• Understanding the clinical presentation and treatment protocols is essential for healthcare providers.
• This highlights the importance of careful patient monitoring during neuroleptic therapy.